Search

Your search keyword '"Bhamidipati, Deepak"' showing total 35 results
Start Over Author "Bhamidipati, Deepak"
35 results on '"Bhamidipati, Deepak"'

7. The Clinical Utility of a Next-Generation Sequencing-Based Approach to Detecting Circulating HPV DNA in Patients with Advanced Anal Cancer.

Author

Bhamidipati, Deepak, Johnson, Jay R., Lin, Kangyu, Pelicano, Helene, Eng, Cathy, Huey, Ryan, Wolff, Robert A., Halperin, Daniel M., Frumovitz, Michael F., Wistuba, Ignacio I., Duose, Dzifa Y., Mallampati, Saradhi, Luthra, Rajyalakshmi, and Morris, Van K.

Subjects
*PAPILLOMAVIRUS diseases, *RESEARCH funding, *DNA, *METASTASIS, *LONGITUDINAL method, *ANAL tumors, *SEQUENCE analysis, *MOLECULAR diagnosis, EPITHELIAL cell tumors
Abstract

Simple Summary: Detecting circulating tumor DNA (ctDNA) in the blood has emerged as a valuable method for evaluating several different cancers. Most anal cancers are caused by HPV infection, which is typically identified through the examination of tissue specimens. In this study, we describe a novel method for detecting HPV in the ctDNA using next-generation DNA sequencing on blood samples from patients with advanced anal cancer. The assay was able to detect multiple types of HPV, including uncommon variants. Additionally, the assay appeared to correlate with the disease burden and response to treatment. HPV DNA can often integrate into cancer DNA, which was detectable using our assay, and we show that this may prognosticate which patients are more resistant to treatment. Background: To extend the practicality of liquid biopsy beyond the historical HPV circulating tumor DNA (ctDNA) assays, we evaluated the clinical relevance of a novel next-generation sequencing HPV ctDNA assay in patients with locally advanced and metastatic squamous cell cancer of the anal canal (mSCCA). Methods: ctDNA isolated from the plasma of patients with mSCCA was sequenced using a 1.4 Mb hybrid-capture target-enrichment panel covering the whole genome sequences of all 193 HPV types. The HPV type, copy number (CN), and integration sites were determined using a bioinformatic pipeline. Results: A total of 77 plasma samples from 28 patients with HPV-related SCCA were retrospectively analyzed. HPV ctDNA was detected in 26 cases (93%) (including uncommon subtypes). The median HPV CN was higher in metastatic versus locally recurrent/unresectable SCCA (p = 0.043). Changes in the HPV CN were concordant with the radiographic response (p = 0.027). An integration event was detected in 23 patients (82%), with presumed episomal HPV DNA present in the remaining patients. Higher HPV integration (a mean of ≥1 integration across samples) was associated with a worse overall survival from the start of immunotherapy (13.6 months versus 36.0 months; p = 0.003). Conclusions: Using HPV-informed next-generation sequencing of the ctDNA, we found changes in the HPV CN correlated with the treatment response and that HPV integration detected in the ctDNA is an unfavorable prognostic biomarker. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

9. Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.

Author

Pellatt, Andrew J., Bhamidipati, Deepak, and Subbiah, Vivek

Subjects
MISSIONARIES, COLORECTAL cancer, CELLULAR signal transduction, GENE expression, MONOCLONAL antibodies, ONCOGENES, GENETIC mutation, CELL receptors, EPIDERMAL growth factor receptors
Abstract

Understanding the landscape of KRAS mutations in #CRC is crucial with over 2.8M annual diagnoses worldwide. Explore promising therapies and ongoing challenges in this comprehensive review. #CancerResearch #KRAS #ColorectalCancer [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Characterizing outcomes of ERBB2-amplified biliary tract cancer.

Author

Fox, Daniel Aaron, primary, Haro-Silerio, Jaime, additional, Bhamidipati, Deepak, additional, Meric-Bernstam, Funda, additional, Pant, Shubham, additional, Ross, Jeffrey S., additional, Hu, Zishuo Ian, additional, Koay, Eugene Jon, additional, Ludmir, Ethan B., additional, Tran Cao, Hop Sanderson, additional, Tzeng, Ching-Wei D., additional, Chun, Yun Shin, additional, Vauthey, Jean-Nicolas, additional, Newhook, Timothy E., additional, Metwalli, Zeyad, additional, Habibollahi, Peiman, additional, Cox, Veronica L., additional, Kang, Hyunseon, additional, Javle, Milind M., additional, and Lee, Sunyoung S., additional

Published
2024
Full Text
View/download PDF

12. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations.

Author

Bhamidipati, Deepak, primary, Haro-Silerio, Jaime, additional, Dumbrava, Ecaterina Elena, additional, Fu, Siqing, additional, Hong, David S., additional, Karp, Daniel D., additional, Naing, Aung, additional, Pant, Shubham, additional, Piha-Paul, Sarina A., additional, Rodon Ahnert, Jordi, additional, Tsimberidou, Apostolia Maria, additional, Johnson, Amber, additional, Lee, Michael Sangmin, additional, Dasari, Arvind, additional, Raghav, Kanwal Pratap Singh, additional, Morris, Van K., additional, Overman, Michael J., additional, Kopetz, Scott, additional, Meric-Bernstam, Funda, additional, and Yap, Timothy A., additional

Published
2024
Full Text
View/download PDF

13. Characterization of outcomes and genomic alterations (GA) in combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA).

Author

Haro-Silerio, Jaime, primary, Fox, Daniel Aaron, additional, Bhamidipati, Deepak, additional, Hu, Zishuo Ian, additional, Koay, Eugene Jon, additional, Ludmir, Ethan B., additional, Tran Cao, Hop Sanderson, additional, Vauthey, Jean-Nicolas, additional, Newhook, Timothy E., additional, Tzeng, Ching-Wei D., additional, Chun, Yun Shin, additional, Mahvash, Armeen, additional, Metwalli, Zeyad, additional, Habibollahi, Peiman, additional, Cox, Veronica L., additional, Kang, Hyunseon, additional, Chatterjee, Deyali, additional, Kaseb, Ahmed Omar, additional, Javle, Milind M., additional, and Lee, Sunyoung S., additional

Published
2024
Full Text
View/download PDF

21. Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy.

Author

Bhamidipati, Deepak, primary, Raghav, Kanwal Pratap Singh, additional, Morris, Van K., additional, Kopetz, Scott, additional, Kee, Bryan K., additional, Johnson, Benny, additional, Willis, Jason, additional, Dasari, Arvind, additional, Morelli, Maria Pia, additional, Parseghian, Christine Megerdichian, additional, Lee, Michael Sangmin, additional, Le, Phat, additional, Shen, John Paul Y.C., additional, Ludford, Kaysia, additional, and Overman, Michael J., additional

Published
2022
Full Text
View/download PDF

23. Abstract 808: Analysis of 1151 prospective research biopsies: Factors influencing tumor yield across patients and biopsy cores

Author

Bhamidipati, Deepak, primary, Verma, Anuj, additional, Maru, Dipen M., additional, Sui, Dawen, additional, Mathew, Grace, additional, Lang, Wenhua, additional, Posadas, Juan F., additional, Hein, Joshua P., additional, Kopetz, Scott, additional, Futreal, Andrew, additional, Wistuba, Ignacio I., additional, Lee, J. Jack, additional, Overman, Michael J., additional, and Tam, Alda L., additional

Published
2020
Full Text
View/download PDF

25. Stereotactic Radiosurgery Practice Patterns for Brain Metastases in the United States: A National Survey

Author

Blomain, Erik S, Kim, MD, Hyun, Garg, Shivank, Bhamidipati, Deepak, Guo, Jenny, Kalchman, Ingrid, McAna, John F., Shi, Wenyin, Blomain, Erik S, Kim, MD, Hyun, Garg, Shivank, Bhamidipati, Deepak, Guo, Jenny, Kalchman, Ingrid, McAna, John F., and Shi, Wenyin

Abstract

Background: Stereotactic radiosurgery (SRS) has emerged as an important modality for the treatment of intracranial metastases. There are currently few established guidelines delineating indications for SRS use and fewer still regarding plan evaluation in the treat- ment of multiple brain metastases. Methods: An 18 question electronic survey was distributed to radiation oncologists at National Cancer Institute (NCI) designated cancer centers in the US (60). Centers without radiation oncologists were excluded. Physicians who indicated that they do not prescribe SRS were excluded from the remaining survey questions. Sign test and Chi-square test were used to determine if responses differed significantly from random distribution. Results: 116 of the 697 radiation oncologists surveyed completed the questionnaire, representing 51 institutions. 62% reported treating patients with brain metastases using SRS. Radiation oncologists prescribing SRS most commonly treat CNS (66.2%) and lung (49.3%) malignancies. SRS was used more frequently for <10 brain metastases (73.7%; p<.0001) and whole brain radiation therapy (WBRT) for >10 brain metastases (82.5%; p<.0001). The maximum number of lesions physicians were willing to treat with SRS without WBRT was 1-4 (40.4%) and 5-10 (42.4%) (p<.0001 compared to 11-15, 16-20 and no limit). The most important criteria for choosing SRS or WBRT were number of lesions (p<.0001) and performance status (p=.016). The most common margin for SRS was 0 mm (49.1%; p=.0021). The most common dose constraints other than critical structure was conformity index (84.2%) and brain V12 (61.4%). The LINAC was the most common treatment modality (54.4%) and mono-isocenter technique for multiple brain metastases was commonly used (43.9%; p=.23). Most departments do not have a policy for brain metastases treatment (64.9%; p=.024). Conclusions: This is one of the first national surveys assessing the use of SRS for brain metastases in clinical practice. These data h

Published
2018

27. Salvage Fractionated Stereotactic Re-irradiation (FSRT) for Patients with Recurrent High Grade Gliomas Progressed after Bevacizumab Treatment

Author

Shi, Wenyin, primary, Blomain, Erik, additional, Siglin, Joshua, additional, Palmer, Joshua, additional, Dan, Tu, additional, Wang, Yang, additional, Werner-Wasik, Maria, additional, Glass, Jon, additional, Kim, Lyndon, additional, Bar-Ad, Voichita, additional, Bhamidipati, Deepak, additional, Evans, James, additional, Judy, Kevin, additional, Farrell, Christopher, additional, and Andrews, David, additional

Published
2018
Full Text
View/download PDF

28. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment

Author

Shi, Wenyin, primary, Blomain, Erik S., additional, Siglin, Joshua, additional, Palmer, Joshua D., additional, Dan, Tu, additional, Wang, Yang, additional, Werner-Wasik, Maria, additional, Glass, Jon, additional, Kim, Lyndon, additional, Bar Ad, Voichita, additional, Bhamidipati, Deepak, additional, Evans, James J., additional, Judy, Kevin, additional, Farrell, Christopher J., additional, and Andrews, David W., additional

Published
2017
Full Text
View/download PDF

30. NIMG-67. PRE-RADIATION TUMOR PROGRESSION IMPROVES PROGNOSTIC STRATIFICATION IN GLIOBLASTOMA PATIENTS

Author

Palmer, Joshua, primary, Shukla, Gaurav, additional, Mollaee, Mehri, additional, Sharma, Dinesh, additional, Skowronski, Jenna, additional, Bhamidipati, Deepak, additional, Champ, Colin, additional, Glass, Jon, additional, Kim, Lyndon, additional, Judy, Kevin, additional, Evans, James, additional, Farrell, Christopher, additional, Andrews, David, additional, Peiper, Stephen, additional, Shi, Wenyin, additional, Wang, Zi-Xuan, additional, and Werner-wasik, Maria, additional

Published
2016
Full Text
View/download PDF

33. Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies

Author

Bhamidipati, Deepak and Subbiah, Vivek

Abstract

Gastrointestinal (GI) malignancies encompass a broad range of tumors with limited treatment options, particularly for advanced disease. With the development and implementation of next-generation sequencing (NGS) in routine practice, molecular-targeting therapies have been increasingly incorporated into the treatment paradigm for various cancers. Several drugs have achieved tissue-agnostic regulatory approvals, which offer promising biomarker-driven therapy options for patients with advanced GI malignancies. In this review, we focus on the clinical evidence for recent drug approvals for neurotrophic tyrosine receptor kinase (NTRK) fusion, microsatellite instability-high (MSI-H) phenotype, tumor mutation burden-high (TMB-H), BRAF V600E, and rearranged during transfection (RET), in the context of GI malignancies. We also highlight the future landscape of tissue-agnostic targets, such as human epidermal growth factor receptor 2 (HER2)/neu, fibroblast growth factor receptor (FGFR), and neuregulin (NRG)-1.

Published
2022
Full Text
View/download PDF

34. Durable Remission After Targeted Therapy in BRAF V600E- Mutant Metastatic Colorectal Cancer: Case Report.

Author

Fox DA, Bhamidipati D, Kopetz S, and Hong DS

Abstract

BRAF mutation leads to constitutive activation of the MAPK pathway and is associated with the immune-activating molecular subtype of colorectal cancer. Targeted therapy for BRAF V600E- mutant metastatic colorectal cancer (CRC) has significantly improved outcomes for these patients when combined with anti-epithelial growth factor receptor (EGFR) therapy. However, most patients ultimately develop disease progression. We report a case of a patient with metastatic-deficient mismatch repair, BRAF V600E- mutated CRC, who achieved a durable complete response to vemurafenib plus cetuximab and chemotherapy despite initial high burden of disease, including peritoneal involvement. Recent clinical trials of combined anti-EGFR/anti -BRAF V600E therapy in BRAF V600E -mutant CRCs have found a few instances of robust response. Further study of combined targeted and chemotherapeutic regimens and the immunogenic properties of BRAF mutation may yield promising results.

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results